The DOI matches its Crossref record; 211 of the 211 references it cites were found in a registry or an index.
Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized cause of liver-related morbidity and mortality. It can develop secondary to numerous causes but a great majority of NAFLD cases occur in patients who are obese or present with other components of metabolic syndrome (hypertension, dyslipidemia, diabetes). This is called primary NAFLD and insulin resistance plays a key role in its pathogenesis. Obesity is characterized by expanded adipose tissue, which is under a state of chronic inflammation. This disturbs the normal storage and endocrine functions of adipose tissue. In obesity, the secretome (adipokines, cytokines, free fatty acids and other lipid moieties) of fatty tissue is amplified, which through its autocrine, paracrine actions in fat tissue and systemic effects especially in the liver leads to an altered metabolic state with insulin resistance (IR). IR leads to hyperglycemia and reactive hyperinsulinemia, which stimulates lipid-accumulating processes and impairs hepatic lipid metabolism. IR enhances free fatty acid delivery to liver from the adipose tissue storage due to uninhibited lipolysis. These changes result in hepatic abnormal fat accumulation, which may initiate the hepatic IR and further aggravate the altered metabolic state of whole body. Hepatic steatosis can also be explained by the fact that there is enhanced dietary fat delivery and physical inactivity. IR and NAFLD are also seen in various lipodystrophic states in contrary to popular belief that these problems only occur due to excessive adiposity in obesity. Hence, altered physiology of adipose tissue is central to development of IR, metabolic syndrome and NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–211 of 211
Effects of Weight Loss Surgeries on Liver Disease
Blackburn, G. L., & Mun, E. C. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-860866 · Cited by 38
Phenomics, Lipodystrophy, and the Metabolic Syndrome
Hegele, R. A. (2004) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2004.02.001 · Cited by 37
Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers
Cassiman, D. M., Libbrecht, L., Desmet, V. I., et al. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)80938-7 · Cited by 37
Regional specificity of ASP binding in human adipose tissue.
Saleh, J., Christou, N., & Cianflone, K. (1999) · American Journal of Physiology. Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.5.e815 · Cited by 35
Acylation-stimulating protein precursor proteins in adipose tissue in human obesity
Xia, Z., & Cianflone, K. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00254-3 · Cited by 34
Should a liver biopsy be done in patients with subclinical chronically elevated transaminases?
dinghen, V. D. L., Combes, M., Trouette, H., Winnock, M., Amouretti, M., de Mascarel, A., & Couzigou, P. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200409000-00011 · Cited by 33
Roden, M. (2001) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-200107000-00003 · Cited by 33
Krug, A. W., & Ehrhart‐Bornstein, M. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-4555-z · Cited by 31
Pascual, E. (1994) · Current Opinion in Rheumatology · doi:10.1097/00002281-199407000-00018 · Cited by 31
Falkner, B. E., Sherif, K., & Kushner, H. (2000) · PubMed · Cited by 16
Isoniazid and Nonalcoholic Steatohepatitis
Novaro, G. M. (1999) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199903000-00023 · Cited by 5
Cited by
Manna, P., & Jain, S. K. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.0095 · Cited by 1,145
Antar, S. A., Ashour, N. A., Sharaky, M., Khattab, M., Ashour, N. A., Zaid, R. T., Roh, E. J., Elkamhawy, A., & Al-Karmalawy, A. A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115734 · Cited by 622
González-Périz, A., Horrillo, R., Ferré, N., Gronert, K., Dong, B., Morán-Salvador, E., Titos, E., Martínez-Clemente, M., López-Parra, M., Arroyo, V., et al. (2009) · The FASEB Journal · doi:10.1096/fj.08-125674 · Cited by 555
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
Argo, C. K., Northup, P. G., Al-Osaimi, A. M. S., & Caldwell, S. H. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.019 · Cited by 552
Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management
Garcia-Compean, D., Jaquez-Quintana, J. O., Gonzalez-Gonzalez, J. A., & Maldonado-Garza, H. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.280 · Cited by 423
Metadata
- Authors
- Qureshi, K.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2007
- Volume
- 13
- Issue
- 26
- Pages
- 3540
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W2101302239
- Cited by
- 283
- References
- 211
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.